- Research article
- Open Access
Accuracy of gadoteridol enhanced MR-angiography in the evaluation of carotid artery stenosis
© Zaccagna et al. 2015
- Received: 13 July 2015
- Accepted: 15 October 2015
- Published: 15 November 2015
To compare image quality and diagnostic performance of Gadoteridol-enhanced MR angiography (MRA) with Gadobutrol-enhanced MRA in the evaluation of carotid artery stenosis.
MRA was performed in 30 patients with carotid stenosis diagnosed at DUS. Patients were randomly assigned to group A (Gadobutrol-enhanced MRA) or group B (Gadoteridol-enhanced MRA). All examinations were performed with a 3T MR system. Image quality was assessed qualitatively by a 3-grade scale and quantitatively with SNR measurements. Diagnostic performance in the assessment of stenosis, plaque length and morphology was evaluated in the two MRA groups by accuracy calculation and RoC curves analysis using CTA as reference standard. Statistically significant differences in SNR and quality scale were evaluated by the Independent-Samples T Test and Mann–Whitney test, while the Z-statistics was used to compare diagnostic accuracy in the two groups.
Image quality was graded adequate to excellent for both GBCAs, without significant differences (p = 0.165). SNR values were not significantly different in group B (Gadoteridol-enhanced MRA) as compared to group A (Gadobutrol-enhanced MRA) (89.32 ± 70.4 vs 81.09 ± 28.38; p = 0.635). Diagnostic accuracy was 94 % for the evaluation of stenosis degree and 94 % for the identification of ulcerated plaques in group A, while it was 93 % for the evaluation of stenosis degree and 76 % for the identification of ulcerated plaques in group B, without statistically significant differences (p = 0.936).
No significant difference in terms of image quality and diagnostic accuracy was observed between Gadoteridol-enhanced MRA and Gadobutrol-enhanced MRA in patients undergoing evaluation of carotid stenosis.
- Contrast Agent
- Internal Carotid Artery
- Positive Predictive Value
- Negative Predictive Value
- Carotid Stenosis
Ischemic stroke is estimated to be responsible for 10 % of all deaths worldwide. It is the second cause of mortality in western countries and the leading cause of mortality in China and Japan . Atherosclerotic disease of the extracranial internal carotid arteries can be recognized as the cause of stroke at least in 25–30 % of patients . Over the last decade, CT-angiography (CTA) and MR-angiography (MRA) have attained a cardinal role in the imaging of carotid arteries thanks to their increasing diagnostic reliability [2–5]. Since the introduction of contrast-enhanced MRA, several gadolinium-based contrast agents (GBCA) have been tested and implemented in clinical practice [6–9], ranging from standard interstitial molecules to high relaxivity and blood-pool agents [4, 9, 10]. Currently, however, there is no common consensus as to which contrast medium should be used for MRA. Gadoteridol (ProHance®, Bracco) is a macrocyclic gadolinium chelate with a recognized low-rate of adverse side effects. Moreover, it is the sole agent approved for high-dose administration (0.3 mmol/kg) due in part to its high stability and thus lower potential for toxicity from long-term heavy metal deposition [11, 12]. Despite the inherent safety of Gadoteridol, only a few studies have evaluated the performance of this contrast medium in MRA [13–16].
The purpose of this study was to prospectively compare the image quality and diagnostic performance of Gadoteridol enhanced MRA with that of Gadobutrol (Gadovist®, Bayer) enhanced MRA in the evaluation of carotid artery stenosis, using CTA as reference standard.
Doppler-ultrasonography (DUS) showing a hemodynamically significant stenosis of the internal carotid artery (PSV 125 cm/s);
Ultrasound examination showing a stenosis of >30 % according to NASCET criteria ;
Ultrasound examination showing a heterogeneous plaque, irregular surface, intra-plaque hemorrhage or ulceration;
Patients with a general contraindication to MRA/CTA examination and/or with a known allergy to contrast agents and/or laboratory signs of renal failure were excluded from the study.
Patients were randomly assigned to group A or B, undergoing MRA after the administration of 0.1 mmol/kg Gadobutrol (0.1 mL/kg) and 0.1 mmol/kg Gadoteridol (0.2 ml/kg), respectively; randomization was performed according to a 2:1 ratio with 2/3 of patients undergoing Gadoteridol enhanced MRA.
All examinations were performed on a 3T system (Discovery MR750, GE Healthcare, Milwaukee-WIS, USA; with peak gradient strength 50 mT/m, peak slew rate 200 mT/m/ms, HD Neurovascular Array configuration 8-channel, 12-element) with the same technical parameters (T1-weighted 3D SPGRE sequence, TR 4.8 ms, TE 1.8, FA 25°, thickness 0.8 mm, matrix 418 × 418) in both groups. A contrast agent bolus was administered with an automatic injector at a rate of 1 ml/s through an 18-gauge cannula placed in the antecubital vein of the right arm, followed by 15 ml of saline solution. The optimal delay between injection and MRA acquisition was visually evaluated by the bolus tracking technique. CTA was performed on a 128-MDCT scanner (Somatom Definition, Siemens Medical System Erlangen, Germany) using a dual-energy protocol (80 kV and 140 kV, 200 mAs, pitch 0.8, slice-thickness 1 mm, recon increment 0.9 mm, matrix 512×512). The optimal delay between contrast administration and scan was evaluated with the bolus-tracking technique, with a region of interest (ROI) placed at the level of the aortic arch and automatic scan triggering with enhancement threshold set at 150 HU. The acquisition was performed after administration of 50 ml of nonionic iodinated contrast material (Iomeprol 400 mgI/ml, Iomeron 400, Bracco, Milan, Italy), followed by the injection of 30 ml of saline solution at a rate of 4 ml/s with the use of a dual-head injector.
An independent observer (B.S. with 8 years of experience in cardiovascular imaging), blinded to the contrast agent used, assessed the quality of all MRA datasets using a 3-point scale (poor: inhomogeneous vessel enhancement, poor intraluminal signal and wall delineation; adequate: homogenous vessel enhancement, sufficient intraluminal signal and wall delineation, motion artifacts that did not impair measurements; excellent: homogenous vessel enhancement, high intraluminal signal, precise wall delineation, no motion artifacts). Quantitative measurements of signal-to-noise ratio (SNR; signal Intensity in the vessel/Standard Deviation (SD) outside the body) were also performed on each dataset by the same observer. More in detail, in each case a vessel ROI was placed in the terminal common carotid artery just proximal to carotid bifurcation, whereas the background-ROIs were obtained for 3 different images, in ghosts-free areas. Two readers (F.Z. with 9 years’ experience and M.A. with 13 years’ experience in MRA of the carotid arteries), who were blinded to the contrast agent used, independently evaluated MRA datasets for the presence and degree of steno-occlusive disease (according to NASCET criteria) and plaque characteristics. All image sets were presented in random order to each reader. An independent reader (I.C. with 18 years’ experience in cardiovascular imaging) evaluated the stenosis degree and plaque characteristics on CTA images.
Statistical analysis was performed using dedicated software (STATA SE 12 for Macintosh; Stata Corporation; College Station, Texas, USA). The normality of each continuous variable group was tested using the Kolmogorov-Smirnov Z test. Continuous data are described as the mean value ± Standard Deviation [95 % confidence interval] or [minimum – maximum] as appropriate; categorical data are expressed as number (percentage). The Mann–Whitney test was applied to determine significant differences in image quality between the two contrast agents. CTA was used as the reference standard for ROC curve analysis and to calculate sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy for stenosis degree and plaque morphology (i.e. plaque ulceration or surface irregularity); a stenosis of 70 % was used as threshold level for stenosis degree. Areas under the curve (AUC) were compared using the Z-statistic to determine differences in diagnostic performance between the two contrast agents . Pearson’s correlation coefficient was used to assess performance in the evaluation of plaque length. Agreement between the two readers was tested using Cohen’s kappa test and was deemed poor for kappa values of 0.21–0.40, fair for values of 0.41–0.60, good for values of 0.61–0.80 and excellent for values of 0.81–1.00 . SNR values were compared using the Independent-Samples T Test. A p value < 0.05 was considered as statistically significant for all tests used.
Table shows demographic and clinical characteristics of the groups; categorical data are expressed as number (percentage), continuous data are described as the mean value ± Standard Deviation [95 % confidence interval] or [minimum – maximum] as appropriate
Gadoteridol (n = 21)
Gadobutrol (n = 9)
14 (66.7 %)
5 (55.6 %)
73.38 ± 6.4 [61–85]
68.56 ± 9.3 [51–81]
71.29 ± 10.9 [53–92]
71.78 ± 11.4 [57–96]
Table shows accuracy, sensibility, specificity, Positive Predictive Value (PPV) and Negative Predictive Value (NPV) of Gadoteridol-enhanced MRA and Gadobutrol-enhanced MRA in determining stenosis degree
Gadoteridol (n = 42)
Gadobutrol (n = 18)
Table shows accuracy, sensibility, specificity, Positive Predictive Value (PPV) and Negative Predictive Value (NPV) of Gadoteridol-enhanced MRA and Gadobutrol-enhanced MRA in plaque morphology evaluation
Gadoteridol (n = 42)
Gadobutrol (n = 18)
The average plaque length was 12.94 ± 6.23 mm [6–20] in group A and 11.9 ± 7.4 mm [4–25] in group B. Pearson’s correlation coefficient revealed a good correlation between MRA and CTA both for Gadoteridol (r = 0.784; p = 0.000) and Gadobutrol (r = 0.751; p = 0.000). Cohen’s kappa revealed excellent agreement in stenosis degree evaluation between the two readers (k = 0.861) and good agreement in morphology detection (k = 0.733) and length determination (k = 0.722).
The implications of this study for routine practice may be relevant in terms of cost and convenience, since Gadoteridol is less expensive (around 80 euros per single dose vial) in comparison with Gadobutrol (around 130 euros per single dose vial). Moreover Gadoteridol is the sole agent approved for high-dose administration (0.3 mmol/kg), due in part to its high stability and lower potential for toxicity from long-term heavy metal deposition [10, 11]; this may represent an additional advantage at lower magnetic fields . Furthermore, the adverse effects of Gadoteridol are reported to be very infrequent; it contains a cyclic nonionic chelate and has a high thermodynamic stability constant (23.8) and a long dissociation half-life (3 h). It’s inclusion in the group of agents considered to be at low risk for Nephrogenic Systemic Fibrosis is probably related to these properties .
It should be noted that this study has some relevant limitations, the most important being the small sample size; however an extended study with a larger patient population is currently ongoing. In addition, digital subtraction angiography was not available for comparison in our series, since just a minority of patients with clinically significant stenosis underwent stenting procedures while the others were treated with endarterectomy without angiography. However, it should be noted that CTA has been shown to be a valid alternative to DSA as reference standard in comparative studies and, in daily clinical practice, it is currently used as the modality of choice for carotid imaging [27, 28]. Another relevant limitation is represented by the inter-individual design of the study; however, this was due to ethical reasons since patients with significant disease are referred for treatment rather than a second contrast-enhanced MRA exam. The final limitation concerns the different sizes of the two patient groups; however, unequal randomization has been reported to be an accepted strategy in clinical trials to gain greater experience when comparing a new treatment to a reference standard, hence we adopted this randomization due to the lack of data on Gadobutrol-enhanced carotid MRA (in this regard it is also worth noting that the statistical power of a 1:1 allocation is 0.95 while the statistical power of a 2:1 ratio is 0.925, with a negligible difference).
In conclusion, from our study, similar results of Gadoteridol-enhanced MRA compared with Gadobutrol-enhanced MRA were observed, both in terms of image quality and diagnostic accuracy, in patients undergoing evaluation of carotid stenosis.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Hasso AN, Stringer WA, Brown KD. Cerebral ischemia and infarction. Neuroimaging Clin N Am. 1994;4(4):733–52.PubMedGoogle Scholar
- Saba L, Mallarini G. Comparison between quantification methods of carotid artery stenosis and computed tomographic angiography. J Comput Assis Tomograf. 2010;34(3):421–30.View ArticleGoogle Scholar
- Clevert DA, Johnson T, Michaely H, Jung EM, Flach PM, Strautz TI, et al. High-grade stenoses of the internal carotid artery: comparison of high-resolution contrast enhanced 3D MRA, duplex sonography and power Doppler imaging. Eur J Radiol. 2006;60(3):379–86.View ArticlePubMedGoogle Scholar
- Anzidei M, Napoli A, Marincola BC, Nofroni I, Geiger D, Zaccagna F, et al. Gadofosveset-enhanced MR angiography of carotid arteries: does steady-state imaging improve accuracy of first-pass imaging? Comparison with selective digital subtraction angiography. Radiology. 2009;251(2):457–66.View ArticlePubMedGoogle Scholar
- Altaf N, Daniels L, Morgan PS, Auer D, MacSweeney ST, Moody AR, et al. Detection of intraplaque hemorrhage by magnetic resonance imaging in symptomatic patients with mild to moderate carotid stenosis predicts recurrent neurological events. J Vasc Surg. 2008;47(2):337–42.View ArticlePubMedGoogle Scholar
- Xing X, Zeng X, Li X, Zhao Q, Kirchin MA, Pirovano G, et al. Contrast-enhanced MR angiography: does a higher relaxivity MR contrast agent permit a reduction of the dose administered for routine vascular imaging applications? Radiol Med. 2015;120(2):239–50.View ArticlePubMedGoogle Scholar
- Anzalone N, Scotti R, Vezzulli P. High relaxivity contrast agents in MR angiography of the carotid arteries. Eur Radiol. 2006;16 Suppl 7:M27–34.View ArticlePubMedGoogle Scholar
- Goyen M, Debatin JF. Gadobenate dimeglumine (MultiHance) for magnetic resonance angiography: review of the literature. Eur Radiol. 2003;13 Suppl 3:N19–27.View ArticlePubMedGoogle Scholar
- Amarteifio E, Essig M, Böckler D, Attigah N, Schuster L, Demirel S. Comparison of gadofosveset (Vasovist®) with gadobenate dimeglumine (Multihance®)-enhanced MR angiography for high-grade carotid artery stenosis. J Neuroradiol. 2014;42(4):236–44.View ArticlePubMedGoogle Scholar
- Aime S, Caravan P. Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. J Magn Reson Imaging. 2009;30(6):1259–67.PubMed CentralView ArticlePubMedGoogle Scholar
- Runge VM, Wells JW. Update: safety, new applications, new MR agents. Top Magn Reson Imaging. 1995;7(3):181–95.PubMedGoogle Scholar
- Shellock FG, Kanal E. Safety of magnetic resonance imaging contrast agents. J Magn Reson Imaging. 1999;10(3):477–84.View ArticlePubMedGoogle Scholar
- Hathout GM, Duh MJ, El-Saden SM. Accuracy of contrast-enhanced MR angiography in predicting angiographic stenosis of the internal carotid artery: linear regression analysis. AJNR Am J Neuroradiol. 2003;24(9):1747–56.PubMedGoogle Scholar
- Froger CL, Duijm LE, Liem YS, Tielbeek AV, Donkers-van Rossum AB, Douwes-Draaijer P, et al. Stenosis detection with MR angiography and digital subtraction angiography in dysfunctional hemodialysis access fistulas and grafts. Radiology. 2005;234(1):284–91.View ArticlePubMedGoogle Scholar
- Hood MN, Ho VB, Foo TK, Marcos HB, Hess SL, Choyke PL. High-resolution gadolinium-enhanced 3D MRA of the infrapopliteal arteries. Lessons for improving bolus-chase peripheral MRA. Magn Reson Imaging. 2002;20(7):543–9.View ArticlePubMedGoogle Scholar
- Bremerich J, Colet JM, Giovenzana GB, Aime S, Scheffler K, Laurent S, et al. Slow clearance gadolinium-based extracellular and intravascular contrast media for three-dimensional MR angiography. J Magn Reson Imaging. 2001;13(4):588–93.View ArticlePubMedGoogle Scholar
- North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med. 1991;325(7):445–53.View ArticleGoogle Scholar
- Hanley JA, McNeil BJ. The meaning and use of the area under a Receiver Operating Characteristic (ROC) curve. Radiology. 1982;143:29–36.View ArticlePubMedGoogle Scholar
- Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–74.View ArticlePubMedGoogle Scholar
- Maravilla KR, Smith MP, Vymazal J, Goyal M, Herman M, Baima JJ, et al. Are there differences between macrocyclic gadolinium contrast agents for brain tumor imaging? Results of a multicenter intraindividual crossover comparison of gadobutrol with gadoteridol (the TRUTH study). AJNR Am J Neuroradiol. 2015;36(1):14–23.View ArticlePubMedGoogle Scholar
- Koenig M, Schulte-Altedorneburg G, Piontek M, Hentsch A, Spangenberg P, Schwenke C, et al. Intra-individual, randomised comparison of the MRI contrast agents gadobutrol versus gadoteridol in patients with primary and secondary brain tumours, evaluated in a blinded read. Eur Radiol. 2013;23(12):3287–95.View ArticlePubMedGoogle Scholar
- Shen Y, Goerner FL, Snyder C, Morelli JN, Hao D, Hu D, et al. T1 relaxivities of gadoliniumbased magnetic resonance contrast agents in human whole blood at 1.5, 3, and 7 T. Invest Radiol. 2015;50(5):330–8.View ArticlePubMedGoogle Scholar
- Hagberg GE, Scheffler K. Effect of r1 and r2 relaxivity of gadolinium-based contrast agents on the T1-weighted MR signal at increasing magnetic field strengths. Contrast Media Mol Imaging. 2013;8(6):456–65.View ArticlePubMedGoogle Scholar
- Salvolini U, Scarabino T. High Field Brain MRI: Use in Clinical Practice. 1st ed. Berlin Heidelberg: Springer; 2006.View ArticleGoogle Scholar
- Rinck PA, Muller RN. Field strength and dose dependence of contrast enhancement by Gadolinium- based MR contrast agents. Eur Radiol. 1999;9:998–1004.View ArticlePubMedGoogle Scholar
- Reilly RF. Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. Clin J Am Soc Nephrol. 2008;3(3):747–51.PubMed CentralView ArticlePubMedGoogle Scholar
- Anderson GB, Ashforth R, Steinke DE, Ferdinandy R, Findlay JM. CT Angiography for the Detection and Characterization of Carotid Artery Bifurcation Disease. Stroke. 2000;31:2168–74.View ArticlePubMedGoogle Scholar
- Herzig R, Burval S, Krupka B, Vlachovà I, Urbanek K, Mares J. Comparison of ultrasonography, CT angiography and digital subtraction angiography in severe carotid stenoses. Eur J Neurol. 2004;11(11):774–81.View ArticlePubMedGoogle Scholar